View Future GrowthVaxxa 과거 순이익 실적과거 기준 점검 0/6Vaxxa은 연평균 25.5%의 비율로 수입이 증가해 온 반면, Entertainment 산업은 연평균 8.1%의 비율로 증가했습니다. 매출은 연평균 46.9%의 비율로 증가했습니다.핵심 정보25.54%순이익 성장률61.73%주당순이익(EPS) 성장률Entertainment 산업 성장률30.34%매출 성장률46.87%자기자본이익률-65.86%순이익률-9.45%최근 순이익 업데이트30 Jun 2026최근 과거 실적 업데이트Reported Earnings • Jul 17Second quarter 2026 earnings released: EPS: kr0 (vs kr0.037 loss in 2Q 2025)Second quarter 2026 results: EPS: kr0 (improved from kr0.037 loss in 2Q 2025). Revenue: kr30.0m (up 52% from 2Q 2025). Net income: kr2.0k (up kr1.60m from 2Q 2025). Profit margin: 0% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 159% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.공고 • Jun 17Vaxxa AB to Report Q2, 2026 Results on Jul 16, 2026Vaxxa AB announced that they will report Q2, 2026 results on Jul 16, 2026공고 • Mar 24Vaxxa AB to Report Q1, 2026 Results on Apr 22, 2026Vaxxa AB announced that they will report Q1, 2026 results on Apr 22, 2026공고 • Sep 24Vaxxa AB to Report Q3, 2025 Results on Oct 23, 2025Vaxxa AB announced that they will report Q3, 2025 results on Oct 23, 2025공고 • Jun 18Vaxxa AB to Report Q2, 2025 Results on Jul 17, 2025Vaxxa AB announced that they will report Q2, 2025 results on Jul 17, 2025공고 • Mar 25Vaxxa AB to Report Q1, 2025 Results on Apr 23, 2025Vaxxa AB announced that they will report Q1, 2025 results on Apr 23, 2025모든 업데이트 보기Recent updatesReported Earnings • Jul 17Second quarter 2026 earnings released: EPS: kr0 (vs kr0.037 loss in 2Q 2025)Second quarter 2026 results: EPS: kr0 (improved from kr0.037 loss in 2Q 2025). Revenue: kr30.0m (up 52% from 2Q 2025). Net income: kr2.0k (up kr1.60m from 2Q 2025). Profit margin: 0% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 159% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.공고 • Jun 17Vaxxa AB to Report Q2, 2026 Results on Jul 16, 2026Vaxxa AB announced that they will report Q2, 2026 results on Jul 16, 2026Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Mar 24Vaxxa AB to Report Q1, 2026 Results on Apr 22, 2026Vaxxa AB announced that they will report Q1, 2026 results on Apr 22, 2026공고 • Sep 24Vaxxa AB to Report Q3, 2025 Results on Oct 23, 2025Vaxxa AB announced that they will report Q3, 2025 results on Oct 23, 2025공고 • Jun 18Vaxxa AB to Report Q2, 2025 Results on Jul 17, 2025Vaxxa AB announced that they will report Q2, 2025 results on Jul 17, 2025공고 • Mar 25Vaxxa AB to Report Q1, 2025 Results on Apr 23, 2025Vaxxa AB announced that they will report Q1, 2025 results on Apr 23, 2025공고 • Jan 22Vaxxa AB to Report Fiscal Year 2024 Results on Feb 20, 2025Vaxxa AB announced that they will report fiscal year 2024 results on Feb 20, 2025Reported Earnings • Oct 17Third quarter 2024 earnings released: EPS: kr0 (vs kr0.035 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0 (improved from kr0.035 loss in 3Q 2023). Revenue: kr22.4m (up 125% from 3Q 2023). Net income: kr7.0k (up kr806.0k from 3Q 2023). Profit margin: 0% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue.New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (29% average weekly change). Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€5.14m market cap, or US$5.72m).New Risk • Jul 21New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€3.53m market cap, or US$3.83m).Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr0.02 (vs kr0.87 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.02 (up from kr0.87 loss in 2Q 2023). Revenue: kr22.5m (up 123% from 2Q 2023). Net income: kr671.0k (up kr2.22m from 2Q 2023). Profit margin: 3.0% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.공고 • Jun 18Vaxxa AB to Report Q2, 2024 Results on Jul 17, 2024Vaxxa AB announced that they will report Q2, 2024 results on Jul 17, 2024Reported Earnings • Apr 10First quarter 2024 earnings released: EPS: kr0.012 (vs kr1.00 loss in 1Q 2023)First quarter 2024 results: EPS: kr0.012 (up from kr1.00 loss in 1Q 2023). Revenue: kr21.1m (up 245% from 1Q 2023). Net income: kr312.0k (up kr2.97m from 1Q 2023). Profit margin: 1.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.공고 • Apr 04Vaxxa AB to Report Q1, 2024 Results on May 03, 2024Vaxxa AB announced that they will report Q1, 2024 results on May 03, 2024공고 • Mar 26Vaxxa AB, Annual General Meeting, Apr 24, 2024Vaxxa AB, Annual General Meeting, Apr 24, 2024.New Risk • Mar 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.4m free cash flow). Share price has been highly volatile over the past 3 months (56% average daily change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€1.94m market cap, or US$2.11m).Reported Earnings • Feb 26Full year 2023 earnings released: kr0.002 loss per share (vs kr0.28 loss in FY 2022)Full year 2023 results: kr0.002 loss per share (improved from kr0.28 loss in FY 2022). Revenue: kr55.6m (up 22% from FY 2022). Net loss: kr5.10m (loss narrowed 90% from FY 2022).New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (100% average weekly change). Earnings have declined by 56% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€2.11m market cap, or US$2.28m). Minor Risk Revenue is less than US$5m (kr41m revenue, or US$3.9m).공고 • Feb 07Vaxxa AB to Report Q3, 2024 Results on Mar 01, 2024Vaxxa AB announced that they will report Q3, 2024 results on Mar 01, 2024공고 • Jan 25Vaxxa AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vaxxa AB announced that they will report fiscal year 2023 results on Feb 23, 2024공고 • Sep 28Vaxxa AB to Report Q3, 2023 Results on Oct 27, 2023Vaxxa AB announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.01 loss per share (vs kr0.02 loss in 2Q 2022)Second quarter 2023 results: kr0.01 loss per share (improved from kr0.02 loss in 2Q 2022). Revenue: kr10.7m (down 19% from 2Q 2022). Net loss: kr1.55m (loss narrowed 61% from 2Q 2022).공고 • Jul 26Vaxxa AB to Report Q2, 2023 Results on Aug 24, 2023Vaxxa AB announced that they will report Q2, 2023 results on Aug 24, 2023공고 • May 22Augeo Group AB, Annual General Meeting, Jun 20, 2023Augeo Group AB, Annual General Meeting, Jun 20, 2023.Reported Earnings • May 22First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr6.42m (up 30% from 1Q 2022). Net loss: kr2.65m (loss narrowed 12% from 1Q 2022).Reported Earnings • Feb 22Full year 2022 earnings released: kr0.28 loss per share (vs kr0.20 loss in FY 2021)Full year 2022 results: kr0.28 loss per share (further deteriorated from kr0.20 loss in FY 2021). Revenue: kr46.9m (up kr45.5m from FY 2021). Net loss: kr51.1m (loss widened 303% from FY 2021).공고 • Jan 23Augeo Group AB to Report Fiscal Year 2022 Results on Feb 21, 2023Augeo Group AB announced that they will report fiscal year 2022 results on Feb 21, 2023Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Nov 02Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr12.7m (up kr11.5m from 3Q 2021). Net loss: kr6.71m (loss widened 308% from 3Q 2021).Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr13.4m (up kr12.3m from 2Q 2021). Net loss: kr3.94m (loss widened 80% from 2Q 2021).Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Apr 04ESEN eSports AB, Annual General Meeting, May 02, 2022ESEN eSports AB, Annual General Meeting, May 02, 2022.Reported Earnings • Oct 31Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr1.20m (up 459% from 3Q 2020). Net loss: kr1.82m (loss narrowed 18% from 3Q 2020).매출 및 비용 세부 내역Vaxxa가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:7WA0 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비30 Jun 2693-99031 Mar 2683-109031 Dec 2577-99030 Sep 2568-34030 Jun 2574-34031 Mar 2576-14031 Dec 248405030 Sep 249206030 Jun 2480-16031 Mar 2468-26031 Dec 2354-55030 Sep 23-4-321030 Jun 23-2-381031 Mar 231-422031 Dec 220-422030 Sep 2232-225030 Jun 2221-175031 Mar 229-145031 Dec 215-136030 Sep 214-75030 Jun 213-86031 Mar 211-75031 Dec 201-64030 Sep 201-54030 Jun 201-43031 Mar 201-53031 Dec 191-53030 Sep 191-63030 Jun 192-53031 Mar 192-53031 Dec 183-43030 Sep 183-43030 Jun 184-43031 Mar 184-43031 Dec 174-44030 Sep 174-33031 Dec 161-120양질의 수익: 7WA0 은(는) 현재 수익성이 없습니다.이익 마진 증가: 7WA0는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 7WA0는 수익성이 없지만 지난 5년 동안 연평균 25.5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 7WA0의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 7WA0은 수익성이 없어 지난 해 수익 성장률을 Entertainment 업계(-6.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 7WA0는 현재 수익성이 없으므로 자본 수익률이 음수(-65.86%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMedia 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/29 18:27종가2026/07/29 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vaxxa AB는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Jul 17Second quarter 2026 earnings released: EPS: kr0 (vs kr0.037 loss in 2Q 2025)Second quarter 2026 results: EPS: kr0 (improved from kr0.037 loss in 2Q 2025). Revenue: kr30.0m (up 52% from 2Q 2025). Net income: kr2.0k (up kr1.60m from 2Q 2025). Profit margin: 0% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 159% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
공고 • Jun 17Vaxxa AB to Report Q2, 2026 Results on Jul 16, 2026Vaxxa AB announced that they will report Q2, 2026 results on Jul 16, 2026
공고 • Mar 24Vaxxa AB to Report Q1, 2026 Results on Apr 22, 2026Vaxxa AB announced that they will report Q1, 2026 results on Apr 22, 2026
공고 • Sep 24Vaxxa AB to Report Q3, 2025 Results on Oct 23, 2025Vaxxa AB announced that they will report Q3, 2025 results on Oct 23, 2025
공고 • Jun 18Vaxxa AB to Report Q2, 2025 Results on Jul 17, 2025Vaxxa AB announced that they will report Q2, 2025 results on Jul 17, 2025
공고 • Mar 25Vaxxa AB to Report Q1, 2025 Results on Apr 23, 2025Vaxxa AB announced that they will report Q1, 2025 results on Apr 23, 2025
Reported Earnings • Jul 17Second quarter 2026 earnings released: EPS: kr0 (vs kr0.037 loss in 2Q 2025)Second quarter 2026 results: EPS: kr0 (improved from kr0.037 loss in 2Q 2025). Revenue: kr30.0m (up 52% from 2Q 2025). Net income: kr2.0k (up kr1.60m from 2Q 2025). Profit margin: 0% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 159% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
공고 • Jun 17Vaxxa AB to Report Q2, 2026 Results on Jul 16, 2026Vaxxa AB announced that they will report Q2, 2026 results on Jul 16, 2026
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Mar 24Vaxxa AB to Report Q1, 2026 Results on Apr 22, 2026Vaxxa AB announced that they will report Q1, 2026 results on Apr 22, 2026
공고 • Sep 24Vaxxa AB to Report Q3, 2025 Results on Oct 23, 2025Vaxxa AB announced that they will report Q3, 2025 results on Oct 23, 2025
공고 • Jun 18Vaxxa AB to Report Q2, 2025 Results on Jul 17, 2025Vaxxa AB announced that they will report Q2, 2025 results on Jul 17, 2025
공고 • Mar 25Vaxxa AB to Report Q1, 2025 Results on Apr 23, 2025Vaxxa AB announced that they will report Q1, 2025 results on Apr 23, 2025
공고 • Jan 22Vaxxa AB to Report Fiscal Year 2024 Results on Feb 20, 2025Vaxxa AB announced that they will report fiscal year 2024 results on Feb 20, 2025
Reported Earnings • Oct 17Third quarter 2024 earnings released: EPS: kr0 (vs kr0.035 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0 (improved from kr0.035 loss in 3Q 2023). Revenue: kr22.4m (up 125% from 3Q 2023). Net income: kr7.0k (up kr806.0k from 3Q 2023). Profit margin: 0% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue.
New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (29% average weekly change). Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€5.14m market cap, or US$5.72m).
New Risk • Jul 21New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€3.53m market cap, or US$3.83m).
Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr0.02 (vs kr0.87 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.02 (up from kr0.87 loss in 2Q 2023). Revenue: kr22.5m (up 123% from 2Q 2023). Net income: kr671.0k (up kr2.22m from 2Q 2023). Profit margin: 3.0% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
공고 • Jun 18Vaxxa AB to Report Q2, 2024 Results on Jul 17, 2024Vaxxa AB announced that they will report Q2, 2024 results on Jul 17, 2024
Reported Earnings • Apr 10First quarter 2024 earnings released: EPS: kr0.012 (vs kr1.00 loss in 1Q 2023)First quarter 2024 results: EPS: kr0.012 (up from kr1.00 loss in 1Q 2023). Revenue: kr21.1m (up 245% from 1Q 2023). Net income: kr312.0k (up kr2.97m from 1Q 2023). Profit margin: 1.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.
공고 • Apr 04Vaxxa AB to Report Q1, 2024 Results on May 03, 2024Vaxxa AB announced that they will report Q1, 2024 results on May 03, 2024
공고 • Mar 26Vaxxa AB, Annual General Meeting, Apr 24, 2024Vaxxa AB, Annual General Meeting, Apr 24, 2024.
New Risk • Mar 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.4m free cash flow). Share price has been highly volatile over the past 3 months (56% average daily change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€1.94m market cap, or US$2.11m).
Reported Earnings • Feb 26Full year 2023 earnings released: kr0.002 loss per share (vs kr0.28 loss in FY 2022)Full year 2023 results: kr0.002 loss per share (improved from kr0.28 loss in FY 2022). Revenue: kr55.6m (up 22% from FY 2022). Net loss: kr5.10m (loss narrowed 90% from FY 2022).
New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (100% average weekly change). Earnings have declined by 56% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€2.11m market cap, or US$2.28m). Minor Risk Revenue is less than US$5m (kr41m revenue, or US$3.9m).
공고 • Feb 07Vaxxa AB to Report Q3, 2024 Results on Mar 01, 2024Vaxxa AB announced that they will report Q3, 2024 results on Mar 01, 2024
공고 • Jan 25Vaxxa AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vaxxa AB announced that they will report fiscal year 2023 results on Feb 23, 2024
공고 • Sep 28Vaxxa AB to Report Q3, 2023 Results on Oct 27, 2023Vaxxa AB announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.01 loss per share (vs kr0.02 loss in 2Q 2022)Second quarter 2023 results: kr0.01 loss per share (improved from kr0.02 loss in 2Q 2022). Revenue: kr10.7m (down 19% from 2Q 2022). Net loss: kr1.55m (loss narrowed 61% from 2Q 2022).
공고 • Jul 26Vaxxa AB to Report Q2, 2023 Results on Aug 24, 2023Vaxxa AB announced that they will report Q2, 2023 results on Aug 24, 2023
공고 • May 22Augeo Group AB, Annual General Meeting, Jun 20, 2023Augeo Group AB, Annual General Meeting, Jun 20, 2023.
Reported Earnings • May 22First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr6.42m (up 30% from 1Q 2022). Net loss: kr2.65m (loss narrowed 12% from 1Q 2022).
Reported Earnings • Feb 22Full year 2022 earnings released: kr0.28 loss per share (vs kr0.20 loss in FY 2021)Full year 2022 results: kr0.28 loss per share (further deteriorated from kr0.20 loss in FY 2021). Revenue: kr46.9m (up kr45.5m from FY 2021). Net loss: kr51.1m (loss widened 303% from FY 2021).
공고 • Jan 23Augeo Group AB to Report Fiscal Year 2022 Results on Feb 21, 2023Augeo Group AB announced that they will report fiscal year 2022 results on Feb 21, 2023
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 02Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr12.7m (up kr11.5m from 3Q 2021). Net loss: kr6.71m (loss widened 308% from 3Q 2021).
Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr13.4m (up kr12.3m from 2Q 2021). Net loss: kr3.94m (loss widened 80% from 2Q 2021).
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Apr 04ESEN eSports AB, Annual General Meeting, May 02, 2022ESEN eSports AB, Annual General Meeting, May 02, 2022.
Reported Earnings • Oct 31Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr1.20m (up 459% from 3Q 2020). Net loss: kr1.82m (loss narrowed 18% from 3Q 2020).